The catastrophic failure of Pfizer's torcetrapib looked like it might doom an entire class of cholesterol modulators, but next month Merck will move its anacetrapib into one of the largest cardiovascular trials ever. Asher Mullard investigates how drug developers have reignited hope for the CETP inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Learning lessons from Pfizer's $800 million failure. Nat Rev Drug Discov 10, 163–164 (2011). https://doi.org/10.1038/nrd3401
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3401
- Springer Nature Limited
This article is cited by
-
Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA
Clinical Pharmacology & Therapeutics (2013)